Mithra Successfully Produces its First Commercial Batch of Myring™ for Europe

/in , /by

• Crucial step taken by Mithra CDMO facility in Belgium with the production of first batch of Myring™, starting the commercial manufacturing process • Production of commercial batches for the European markets on target • Production capacity to be tripled, thanks to investment in state-of-the-art technology Liege, Belgium, 13 February 2019 – 7 :30 CET […]

Read more →

Mithra Signs Exclusive License and Supply Agreement for Commercialization of Myring™ in the Middle East

/in , /by

Mithra strengthens its collaboration with UAE-based ITROM Pharmaceutical Group with a consolidated deal to generate at least EUR 14 million Product to be manufactured at Mithra CDMO facility in Belgium Agreement follows licensing deals for Myring™ with market leaders in the US, Europe, Russia, Australia and Chile Liège, Belgium, 12 February 2019 – 7 :30 CET […]

Read more →

Mithra Strengthens Management Team With Key Appointments

/in , /by

Expansion of IR and Communications functions to support the execution of Mithra’s strategy Liège, Belgium, 4 February 2019 – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces it has strengthened its IR and Communications functions with the appointments of Ms. Alexandra Deschner as Investor Relations Officer and Ms. Maud Vanderthommen as […]

Read more →

Mithra Announces Positive Top-line Results of Estelle® Phase III Oral Contraceptive Study in U.S/Canada

/in , /by

Primary efficacy endpoint indicates excellent contraceptive efficacy, with a Pearl Index (PI) of 2.41 per 100 women, in line with expectations Key secondary endpoints achieved, including excellent bleeding profile, cycle control, quality of life and safety and tolerability Data in line with previously announced Phase III trial in EU / Russia confirming Estelle’s®outstanding profile as […]

Read more →

Mithra announces 2019 financial calendar

/in , /by

Liege, Belgium, 22 January 2019 – 7:30  CET – Mithra (Euronext Brussels: MITRA), a company focused on women’s health, today announces its financial calendar for 2019 : 1 March 2019 : Full Year Results 2018 8 April 2019 : Annual Report 2018 16 May 2019 : Annual General Shareholders Meeting 19 September 2019 : Interim report […]

Read more →

Mithra Wins BelMid Company of the Year 2018

/in , /by

Liège, Belgium, 18 January 2019 – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, has been awarded BelMid Company of the Year 2018 by Euronext Brussels at its annual New Year’s Ceremony held in Brussels last night.

Read more →

Blockbuster Potential in Perimenopause with new E4 Candidate and Acceleration of Donesta Phase III Program

/in , /by

Potential for new perimenopause product candidate PeriNesta launch as early as 2023, with an estimated market opportunity of at least 18 million patients annually in the US and key EU markets Donesta® phase III E4 monotherapy patient recruitment anticipated to start in Q3 2019 pending approvals , potential market authorisation by end 2023 Ongoing global […]

Read more →

Mithra Announces Attendance at the 37th Annual J.P. Morgan Healthcare Conference

/in , /by

Liège, Belgium, 04 January 2019 – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces that Chief Executive Officer Mr. François Fornieri and members of the executive management team will be attending the 37th Annual J.P. Morgan Healthcare Conference in San Francisco from the 7th to the 10th of January 2019. For […]

Read more →

Mithra Announces Complex Therapeutics Update

/in , /by

Positive study results from three-month formulation of Zoreline®, allowing progression to final clinical studies Pivotal trial will commence in Q1 2019, as previously expected Licensing agreement signed with UAE-based ITROM Pharmaceutical Group Liège, Belgium, 21 December 2018 – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces positive results from its three-month […]

Read more →

Mithra Announces Myring™ Update

/in , /by

Mithra’s US partner Mayne Pharma receives complete response letter for Myring™ Increased manufacturing capacity to meet market demand following licensing deals with market leaders in the US, Austria, Czech Republic, Chile, Denmark, Russia, Australia and New Zealand Launch of Myring™ EU production in January 2019 Liège, Belgium, 14 December 2018, 17:45 CET – Mithra (Euronext […]

Read more →